Blue Bell, Pennsylvania, April 8, 2024 – IPS-Integrated Project Services, LLC, a leading provider of engineering, procurement, construction management, and validation (EPCMV) services in the life sciences sector, is strategically expanding into the Texas market. With a portfolio comprising over 100 projects in the state, IPS has solidified its reputation as a trusted partner for local clients. Leveraging its 35 years of life sciences experience and expertise, IPS aims to drive forward the next generation of life-saving therapies in collaboration with local stakeholders.
Patrick Bucklen, Vice President of IPS and Regional Leader now residing in Houston, brings decades of experience in delivering life sciences projects in the United States and China. Having worked at IPS for more than 25 years, he expressed enthusiasm about the company’s expansion into Texas, stating, “As a firm with a proven history of success on projects across the state, we are uniquely positioned to bring global resources and subject matter expertise to local pharmaceutical, aseptic, cell therapy, gene therapy, compounding pharmacy, medical devices, and research and development (R&D) sectors. Our ability to combine global expertise with local talent will drive design innovation and regulatory compliance in the evolving life sciences landscape.”
IPS has developed a unique EPCMV delivery model, which will provide clients in Texas with a comprehensive and flexible approach to support research and development and manufacturing facility scale-up. This model ensures efficiency, cost-effectiveness, and quality throughout the project lifecycle, from initial concept to final validation, accelerating time-to-market for life-saving therapies. IPS continues to seek out and find the best engineers, subject matter experts and architects to support growing needs in the state to augment our presence in Houston, Austin, and Dallas.
By investing in strategic growth in Texas, IPS is poised to contribute significantly to the region’s economic development while reinforcing its commitment to shaping the future of healthcare.
